loading page

Second Cancer Risk in Childhood Cancer Survivors Treated With Intensity-Modulated Radiation Therapy (IMRT): An Updated Analysis of More Than 10 Years of Follow-Up
  • +4
  • Kathryn Tringale,
  • Dana Casey,
  • Gregory Niyazov,
  • Jessica Lavery,
  • Chaya Moskowitz,
  • Danielle Novetsky Friedman,
  • Suzanne Wolden
Kathryn Tringale
Memorial Sloan Kettering Cancer Center

Corresponding Author:tringalk@mskcc.org

Author Profile
Dana Casey
University of North Carolina System
Author Profile
Gregory Niyazov
Memorial Sloan Kettering Cancer Center
Author Profile
Jessica Lavery
Memorial Sloan Kettering Cancer Center
Author Profile
Chaya Moskowitz
Memorial Sloan Kettering Cancer Center
Author Profile
Danielle Novetsky Friedman
Memorial Sloan Kettering
Author Profile
Suzanne Wolden
Memorial Sloan Kettering Cancer Center
Author Profile

Abstract

Background It is unclear how intensity-modulated radiation therapy (IMRT) impacts long-term risk of second malignant neoplasms (SMNs) in childhood cancer patients. Procedure Patients aged 10 years, many solid SMNs after IMRT in childhood cancer survivors develop in the high dose region. These data serve as a foundation for comparison with other modalities of radiation treatment (e.g., proton therapy).
22 Dec 2021Submitted to Pediatric Blood & Cancer
22 Dec 2021Submission Checks Completed
22 Dec 2021Assigned to Editor
24 Dec 2021Reviewer(s) Assigned
05 Jan 2022Review(s) Completed, Editorial Evaluation Pending
08 Jan 2022Editorial Decision: Revise Major
24 Jan 2022Submission Checks Completed
24 Jan 2022Assigned to Editor
24 Jan 20221st Revision Received
25 Jan 2022Reviewer(s) Assigned
29 Jan 2022Review(s) Completed, Editorial Evaluation Pending
29 Jan 2022Editorial Decision: Accept
May 2022Published in Pediatric Blood & Cancer volume 69 issue 5. 10.1002/pbc.29600